The difference of the effect of ARB on blood pressure and CARDIac functiOn in patients with essential hypertension

The difference of the effect of ARB on blood pressure and CARDIac functiOn in patients with essential hypertension - CARDIO Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009847

Enrollment

Registered

2013-01-23

Start date

2012-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

olmesartan20mg azilsatan20mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Receiving treatment with ARB usual dose(except for olmesartan and azilsartan) for more than six weeks before registration

Exclusion criteria

Exclusion criteria: 1)Hypertensive emergency that requires intravenous administration of antihypertensives 2)Receiving treatment with olmesartan or azilesartan in less than 8 weeks before registration 3)Receiving treatment with Aldosterone antagonists in less than 8 weeks before registration 4)Secondary hypertension 5) Nephritic syndrome 6)Severe renal disease 7)Severe hepatic and biliary tract dysfunction 8) History of cardiovascular events and malignancy within less than 6weeks before registration 9) Pregnancy,the possibility of pregnancy, or the desire to become pregnant.

Design outcomes

Primary

Measure	Time frame
Blood pressure Cardiac function	—

Secondary

Measure	Time frame
Endocrine parameters Vascular function Renal function	—

Countries

Japan

Contacts

Public ContactTakeshi Takami

Clinic Jingumae Internal Medicine

takami66@m5.kcn.ne.jp0744-23-8568

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026